(CercleFinance.com) – UBS reaffirms its ‘buy’ recommendation on Merck KGaA with a price target raised from 172 to 186 euros, a new target which contains 17% upside potential for the stock of the German chemicals and health group .
The broker explains that it is updating its model to take into account the results of the last quarter of 2023, with an increase in the valuations of the life sciences and electronics activities as part of its SOTP (sum of the parts) methodology.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
